Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Apogee Therapeutics Inc. is a clinical-stage biotechnology company advancing potential treatments for asthma and chronic obstructive pulmonary disease (COPD). On June 22,...
— Mario J. Gabelli, CFA, Willis Brucker
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Apogee Therapeutics Inc.
No other institutional pitches found for this ticker yet.
More institutional theses from The Gabelli ABC Fund
Atkore Inc. (0.8% of net assets as of September 30, 2026) (ATKR - $94.75 - NYSE) is a manufacturer of electrical infrastructure products for commercial, industrial, data center, and solar applications. p.A. agreed to...
Our top contributors to performance for the quarter (based upon price change and position size) were Crinetics Pharmaceuticals Inc. (position closed during the quarter), Fox Corp. Class B (1.7% of net assets as of September 30, 2026), Warner Bros. Discovery Inc. (1.9%),...
Our top contributors to performance for the quarter (based upon price change and position size) were Crinetics Pharmaceuticals Inc. (position closed during the quarter), Fox Corp. Class B (1.7% of net assets as of September 30, 2026), Warner Bros. Discovery Inc. (1.9%),...